Home-based transcranial static magnetic field stimulation of the motor cortex for treating levodopa-induced dyskinesias in Parkinson’s disease
Objective: To investigate the potential of transcranial static magnetic field stimulation (tSMS) as a non-pharmacological, non-invasive, home-based treatment to manage levodopa-induced dyskinesias (LIDs) in Parkinson’s…Real-world evidence and feasibility of telemedicine for Parkinson’s disease
Objective: This work aims to provide real-world evidence for the feasibility of telemedicine in Parkinson’s disease (PD). Adherence data presented pertain to patients paying out…Changes in gait and mobility measures collected in daily living conditions, in different stages of Parkinson’s disease
Objective: To explore mobility measures collected in daily-living conditions in different stages of PD. Background: Gait and mobility impairments are considered a cardinal sign in…IMPACT OF DEEP BRAIN STIMULATION ELECTRODE POSITION ON GAIT IN PATIENTS WITH PARKINSON’S DISEASE
Objective: The aim of our study is to evaluate the impact of the deep brain stimulation (DBS) electrode position within the subthalamic nucleus on gait…Plasma biomarkers of disease progression in Parkinson’s disease
Objective: To identify the ability of a panel of plasma biomarkers to predict disease progression in PD patients Background: Plasma neurofilament light chain (NfL) has…Blood neurofilament light chain as a biomarker of Parkinson’s disease
Objective: The objective of the study was to analyse blood neurofilament light chain (NfL) levels in patients with Parkinson’s disease (PD) and healthy controls (HCs),…Initial Postmarketing Real World Experience with directSTIM™ DBS System: A Case Series
Objective: In this study we report the first three cases of a new, CE-marked system for deep brain stimulation. Background: The PMCF study is a…Impact of foslevodopa/foscarbidopa on key clinical and patient-reported outcomes in patients with aPD: Responder analysis of two Phase 3 clinical trials
Objective: To evaluate the effect of foslevodopa/foscarbidopa (LDP/CDP, ABBV-951) on clinical and patient-reported outcomes in advanced Parkinson’s disease (aPD) patients using minimal clinically important difference…Monogenic Hub of the Global Parkinson’s Genetics Program (GP2): In search of new PD genes
Objective: To identify novel monogenic causes of Parkinson’s disease (PD) by performing short and long-read sequencing for up to 10,000 PD patients and families with…Heart rate variability is affected by standing and medication intake in Parkinson’s disease
Objective: To evaluate the effect of levodopa and orthostatism on heart rate variability (HRV) in a sample of consecutive subjects with Parkinson's disease (PD). Background:…
- « Previous Page
- 1
- …
- 219
- 220
- 221
- 222
- 223
- …
- 338
- Next Page »